Genprex

Reprogramming the course of cancer and diabetes

Technologies

Our technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options.

Pipeline

We are developing gene therapies for patients with cancer and diabetes to bring new therapies to large patient populations. Our lead product candidate, REQORSA™ immunogene therapy, is designed to be administered in combination with other therapies, including targeted therapies and immunotherapies, for non-small cell lung cancer.

Management Team

We have assembled a multidisciplinary team of executives and advisors with broad business experience in the biotech and pharmaceutical industries, and research and clinical experience at preeminent medical and academic institutions around the world. Our management team pairs an unmatched expertise with a knack for innovation in research.

Learn More

About Us


At Genprex, we are committed to developing life-changing gene therapies for patients with cancer and diabetes through unique, innovative science. We are dedicated in our efforts to helping patients with limited or no treatment options to have access to new and advanced therapies to more effectively treat their disease. 

What they’re saying

In the Media


Catch up with our

Latest News


Genprex to Participate in Upcoming March Investor Conferences

Investor presentations to highlight novel gene therapies for cancer and diabetes

2 Austin medical companies expect to raise millions with stock offerings

Two Austin-based companies involved in medial research say they expect to raise millions of dollars with stock offerings this week.

Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants

Genprex has entered into securities purchase agreements with two healthcare-dedicated institutional investors for the purchase and sale of 4,000,000 shares of its common stock at a purchase price of $6.25 per share in a registered direct offering priced at-the-market under Nasdaq rules.

Genprex Announces Formation of Clinical Advisory Board

World reknowned medical and clinical experts to guide Genprex’ novel gene therapy clinical development programs in cancer and diabetes, including its two upcoming clinical trials in lung cancer